Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that hydroxycinnamate derivatives, especially a compound named 10a, effectively inhibited SRD5A1 activity and protein expression in cell assays, suggesting potential for treating androgen-related conditions.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.

This study found that integrating Lactobacillus-rich probiotic nutrition and fractional CO₂ laser therapy with clotrimazole in mucoadhesive hydrogels significantly improved clinical and structural outcomes for women with recurrent vulvovaginal candidiasis, suggesting a promising advanced therapy, though further validation in larger trials is needed.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This study found that men with early-onset androgenic alopecia are less responsive to the cardiometabolic effects of bromocriptine compared to men with normal hair growth.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study reported that both phlebotomy and oral contraceptive pills with cyproterone acetate effectively improved insulin resistance and androgenic profiles in women with PCOS, but OCs had more impact on regularizing menstrual cycles.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study found that antiandrogenic pretreatment with combined oral contraceptives did not improve ovulation and pregnancy outcomes compared to direct letrozole induction in women with PCOS.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

This review examines emerging and past therapies for recurrent implantation failure, focusing on three innovative strategies: PBMC, G-CSF, and PRP, but reports no new clinical results.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.